Congestive Heart Failure and Psoriasis
Dr Cohen explores the epidemiologic link between psoriasis and congestive heart failure (CHF), emphasizing the potential risks of TNF-alpha inhibitors in these patients. A randomized trial of infliximab showed no benefit in CHF patients, with higher doses linked to worse outcomes. Case reports also highlight new-onset or worsening CHF with TNF inhibitors. The discussion underscores the importance of avoiding TNF inhibitors in severe CHF (NYHA Class III/IV) and understanding the broader cardiovascular implications of psoriasis treatment.
Jeffrey M. Cohen, MD is a board-certified medical dermatologist and the director of the psoriasis treatment program at the Yale School of Medicine in New Haven, CT.
© 2025 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of The Dermatologist or HMP Global, their employees, and affiliates.
The APP Institute is dedicated to educating and informing advanced practice providers on clinical topics and practical issues to support the profession and improve the quality of patient care across the spectrum of dermatology.
The APP Institute | Dermatology is designed for Advanced Practice Providers who specialize in Dermatology, to further their education and increase their knowledge to achieve better patient outcomes. Explore cutting-edge research, innovative treatment options, and new therapeutic methods, while remaining focused on the fundamental principles and terminology associated with Dermatology. Engage year-round with the Dermatology Learning Network to access clinical insights, interactive features, research news updates, accredited continuing education programs, and more.
